In partnership with
Your competitor just replied. You're still typing.
A lead comes in on Instagram. Another on Messenger. Three more on SMS.
Your team switches tabs, repeats answers, and loses context while hot leads wait hours for replies. At 2am, nobody responds at all.
That’s not a people problem. It’s a process problem.
Wati brings Instagram DM, Facebook Messenger, TikTok, WhatsApp, SMS, RCS, and web chat into one AI-powered inbox. Automations instantly respond, qualify leads, and route conversations to the right person, 24/7.
Your team stops firefighting. Your leads stop waiting. Your pipeline starts moving.
MBS Digest
Fellowship training meets the GLP-1 era
This JACS article addresses a question that bariatric programs are already living with: how fellowship training should adapt as GLP-1 therapy changes referral patterns, patient expectations, and the case mix seen by trainees. The article is indexed as a workforce-focused discussion rather than a clinical outcomes trial, so the important signal is educational, not procedural. Its placement at the top of the ballot reflects how quickly pharmacotherapy has moved from a parallel treatment option to a force shaping surgical training pipelines.
For bariatric surgeons, the issue is not whether medications reduce the need for surgical expertise. It is whether fellowships are preparing graduates to lead multidisciplinary metabolic care, manage combination therapy, counsel patients after medication failure, and handle more complex revisional or rescue scenarios. Programs that treat GLP-1s as outside the surgical lane risk training surgeons for yesterday's practice model.
Korean adolescent sleeve data add an Asian cohort to pediatric MBS outcomes
This single-center retrospective analysis reviewed 24 Korean adolescents with severe obesity who underwent laparoscopic sleeve gastrectomy between 2020 and 2025. At 12 months, mean excess weight loss and excess BMI loss were both roughly 84%, with fat mass falling by about half while muscle mass was relatively preserved. Triglycerides, fasting C-peptide, controlled attenuation parameter, and liver stiffness all improved over the first postoperative year.
The cohort is small, but it adds needed data in an Asian adolescent population where pediatric bariatric evidence remains thinner than in Western series. For surgeons, the hepatic and metabolic improvements are particularly relevant because adolescent programs increasingly evaluate patients with early MASLD risk. The practical message is to build adolescent pathways that protect lean mass, monitor micronutrition closely, and coordinate long-term family support rather than treating sleeve gastrectomy as a one-year intervention.
Patient-reported barriers predict how bariatric recovery feels and performs
This retrospective cohort linked survey responses from 246 sleeve gastrectomy and gastric bypass patients to postoperative outcomes at a single academic center. The survey captured access to care, inpatient experience, recovery, and social needs, with Spanish-language and telephone options available. Low-income respondents were more likely to feel unprepared for discharge, report more postoperative pain than expected, have less support at home, and experience readmission.
The most actionable findings involved routine postoperative resources. Difficulty affording protein shakes or multivitamins was associated with lower 12-month total body weight loss, and limited exercise-equipment access tracked with longer length of stay. Bariatric programs should read this as an operations paper: discharge readiness, supplement affordability, language access, and recovery support are not soft variables. They are part of the outcome pathway.
Revisional bariatric surgery in older adults carries modest but real short-term risk
Using MBSAQIP data from 2020 through 2024, this analysis compared 118,208 revision or conversion procedures in adults 18 to 65 years old versus those older than 65. Older adults represented 6.8% of the cohort and had more baseline comorbidity despite lower BMI. After adjustment, age over 65 was associated with higher odds of major complications, leak, and reoperation, along with longer operative time and slightly longer length of stay.
The study does not argue against revisional surgery in older patients. It argues against casual equivalence. For surgeons, the counseling should be procedure-specific and grounded in physiologic reserve, frailty, indication, anatomy, and the availability of nonoperative alternatives. Older patients may still benefit, but revisional decisions need tighter perioperative planning and a lower threshold for multidisciplinary review.
Obesity-drug comparisons show weight loss, tradeoffs, and uneven outcome data
This systematic review and network meta-analysis included 262 randomized trials with 99,791 participants and compared 19 medications for overweight or obesity. At one year, moderate- to high-certainty evidence supported the largest weight reductions with tirzepatide, CagriSema, oral semaglutide, orforglipron, subcutaneous semaglutide, and phentermine-topiramate. Some emerging agents looked promising, but the certainty was lower.
The study also gives clinicians a useful counterweight to headline weight-loss rankings. Larger losses often came with more gastrointestinal events, fatigue, and discontinuation. Subcutaneous semaglutide had the clearest signal for all-cause mortality and myocardial infarction reduction, while quality-of-life gains and kidney outcomes were less certain across much of the field. Bariatric teams can use this type of comparative evidence to frame medication as part of metabolic care rather than as a simple substitute for surgery.
Obesity and cancer review sharpens the liver-risk discussion
This JAMA comment responds to a broader review on obesity and cancer by focusing on hepatobiliary malignancy. The authors argue that liver cancer is difficult to treat as just another obesity-associated cancer because hepatic risk often runs through steatosis, inflammation, fibrosis, and architectural liver injury. In that frame, BMI is an incomplete proxy for cancer risk.
For bariatric and metabolic surgeons, the point matters because many patients arrive with obesity, diabetes, MASLD, or early fibrosis rather than a single isolated risk factor. Risk stratification should not stop at body size. Programs that track liver disease severity, metabolic control, and fibrosis regression can better explain why durable weight loss may matter for cancer prevention, not only diabetes remission.
Orforglipron beats dapagliflozin on glycemic control, with GLP-1 tolerability limits
ACHIEVE-2 was a 40-week, multicenter, randomized phase 3 trial comparing once-daily oral orforglipron at three doses with dapagliflozin 10 mg in adults with type 2 diabetes inadequately controlled on metformin. The trial randomized 962 participants across 73 sites in six countries. All orforglipron doses were noninferior and statistically superior to dapagliflozin for HbA1c reduction, with the 36 mg dose lowering HbA1c by 1.56% versus 0.81% for dapagliflozin.
The tradeoff was tolerability. Gastrointestinal adverse events occurred in 46% to 54% of orforglipron recipients compared with 12% on dapagliflozin, and discontinuation was higher across the orforglipron arms. For bariatric surgeons, the oral GLP-1 pipeline will likely expand the pool of medically treated patients, but discontinuation, inadequate response, and medication access will keep surgery central in long-term metabolic care.
Setmelanotide phase 3 trial validates a targeted path for hypothalamic obesity
This phase 3 trial randomized 120 patients with acquired hypothalamic obesity to daily setmelanotide or placebo for 52 weeks after dose escalation. Eligible participants were at least 4 years old and had obesity after a hypothalamic tumor, lesion, or injury. Setmelanotide reduced BMI by 16.5%, while placebo was associated with a 3.3% increase, and hunger scores improved more with active treatment.
This is a distinct obesity phenotype, not a general obesity-drug story. For surgeons, the study reinforces that hypothalamic obesity behaves differently from common polygenic obesity and may respond poorly to standard behavioral or procedural logic. MBS evaluation in these patients should be especially cautious, with attention to neuroendocrine drivers, hunger physiology, and realistic expectations for surgery versus targeted pharmacotherapy.
EndoBarrier trial revives the metabolic-device conversation
The ENDO trial randomized 320 patients with poorly controlled type 2 diabetes and obesity to a duodenal-jejunal bypass liner or sham procedure, both with medical management and lifestyle modification. At 12 months, HbA1c fell by 1.10% with the device compared with 0.28% in the sham group, and total weight loss was 7.7% versus 2.1%. More device patients reached HbA1c of 7% or lower and at least 5% total weight loss.
The safety signal is central to interpretation. Device-related serious adverse events occurred in 9.4%, including intolerance, hemorrhage, and hepatic abscess, with hepatic abscess stopping the study early. Surgeons and endoscopists should view this as meaningful efficacy paired with a safety profile that demands disciplined patient selection, structured monitoring, and honest counseling if the technology returns to broader use.
Secret-shopper data expose thin oversight in online GLP-1 prescribing
STAT reported on a JAMA secret-shopper study that tested 49 direct-to-consumer GLP-1 prescribing websites. The publicly available details and related coverage describe a market where prescriptions could often be obtained quickly, with limited real-time clinician engagement and variable screening. The study comes as compounded semaglutide and tirzepatide channels have expanded around demand, cost, and access gaps.
For bariatric practices, the issue is not telehealth itself. It is the difference between structured obesity care and transactional prescribing. Patients may present after rapid medication starts, side effects, dosing confusion, compounded-product exposure, or no nutrition and surgical-candidacy assessment at all. MBS programs should be ready to document medication history carefully and to explain what accountable longitudinal metabolic care looks like.
OpenEvidence adds evidence grading to AI-assisted clinical answers
OpenEvidence announced EvidenceGrade, a feature intended to attach a real-time certainty rating to clinical answers generated from the medical literature. The company describes a two-phase system that first evaluates individual papers for quality, certainty, and relevance, then grades the body of evidence using a GRADE-inspired approach. The goal is to give clinicians a quick signal about how strong the evidence is behind an answer without waiting for a formal systematic review process.
This matters for metabolic and bariatric care because surgeons increasingly face AI-mediated claims from patients, trainees, industry, and even colleagues. A visible evidence grade may reduce overconfidence, but it can also create a false sense of precision if users do not understand how retrieval and grading work. Bariatric surgeons should welcome transparency while keeping a healthy skepticism about any automated grade that collapses messy evidence into a letter.
Humanoid robot surgery remains proof of concept, not practice change
Popular Science reported on a preclinical proof-of-concept in which remotely controlled humanoid robots assisted in two gallbladder procedures in large, non-primate mammals. The systems were smaller and more portable than traditional robotic platforms, but the report also described repeated recalibration and latency problems. The work was presented as an early step toward less bulky surgical robotics, not as a platform ready for clinical deployment.
For bariatric and minimally invasive surgeons, the interesting question is not whether humanoid robots are about to enter the OR. They are not. The question is whether lower-cost, smaller-footprint robotic systems could eventually change access in rural, military, disaster, or space-constrained settings. Any bariatric relevance will depend on reliability, sterility, instrument control, credentialing, and outcomes data, not the shape of the robot.
Poison-center calls rise after GLP-1 weight-loss approval
Endocrinology Advisor summarized a Journal of Medical Toxicology analysis of GLP-1 receptor agonist exposures reported to U.S. poison centers from 2012 through 2023. The investigators compared reporting before and after the July 2021 FDA approval for weight loss and included 10,033 exposures. Postapproval, semaglutide accounted for nearly two-thirds of cases, and calls shifted toward younger and more female patients.
Most cases involved unintentional therapeutic errors and mild gastrointestinal symptoms, but the proportion managed in or referred to a healthcare facility increased from 23.0% to 33.5%. For bariatric practices, this is a patient-education and medication-reconciliation issue. Injection technique, dose escalation, compounded-product confusion, and overlapping prescriptions should be reviewed as carefully as surgical medication holds.
GLP-1 benefit rankings need a harms conversation
MedPage Today covered the BMJ network meta-analysis comparing obesity medications across weight loss, cardiovascular outcomes, adverse events, and quality of life. The report emphasized that several GLP-1-based therapies produced substantial one-year weight loss, with tirzepatide and CagriSema near the top of the ranking. It also noted that only some agents showed clearer cardiometabolic outcome signals, while quality-of-life effects were uncertain.
For surgeons, this reinforces a practical counseling point: medication choice is not just a percent-weight-loss contest. Patients need to understand side effects, treatment persistence, price, access, comorbidity priorities, and what happens if therapy stops. The marketplace will keep promoting comparative weight loss; bariatric teams should keep the conversation anchored in durable health outcomes.
Oral obesity pills are becoming the next market battleground
Reuters reviewed the accelerating race to develop oral obesity drugs, including programs from Novo Nordisk, Eli Lilly, Structure Therapeutics, Merck, AstraZeneca, Roche, Kailera, and others. The report noted Kailera's China data showing up to 10.9% weight loss at week 44 for HRS-7535 and described ongoing pressure from generic competition, falling U.S. prices, and revised market forecasts. Oral agents are now positioned as the next commercial frontier after injectable GLP-1 growth.
For bariatric surgeons, oral therapy could broaden obesity treatment access and lower the friction of starting medication. It could also increase the number of patients cycling through partial response, intolerance, regain, or payer-driven interruptions before surgical referral. Practices should prepare for more patients who have tried multiple medications and need help understanding where surgery fits in a crowded therapeutic sequence.
Online sellers show why GLP-1 access and accountability must travel together
AJMC reported detailed findings from the same JAMA secret-shopper study of 49 online GLP-1 sellers. Forty-five sites issued a prescription, 34 shipped medication, and the median time to prescription was one day or less. Screening gaps were common, including limited assessment of eating-disorder history, lifestyle efforts, weight-loss goals, patient-reported clinical values, and real-time clinician visits.
This is a marketplace story with direct clinical consequences. Limited insurance coverage and high branded-drug prices push patients toward faster channels, but speed can come at the expense of diagnostic rigor and longitudinal care. Bariatric programs can differentiate themselves by offering comprehensive obesity evaluation, safe medication integration, and clear escalation pathways to surgery when indicated.
Find this useful? Forward it to a colleague.
MBS Digest is free and built for the metabolic surgery and obesity medicine community. A peer recommendation is worth more than any ad.